BR112012011783A2 - "métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória via detecção à base de proteína de soro de composições de polímero de sequência aleatória." - Google Patents

"métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória via detecção à base de proteína de soro de composições de polímero de sequência aleatória."

Info

Publication number
BR112012011783A2
BR112012011783A2 BR112012011783A BR112012011783A BR112012011783A2 BR 112012011783 A2 BR112012011783 A2 BR 112012011783A2 BR 112012011783 A BR112012011783 A BR 112012011783A BR 112012011783 A BR112012011783 A BR 112012011783A BR 112012011783 A2 BR112012011783 A2 BR 112012011783A2
Authority
BR
Brazil
Prior art keywords
methods
random sequence
polymer compositions
sequence polymer
compositions
Prior art date
Application number
BR112012011783A
Other languages
English (en)
Inventor
Zanelli Eric
Krieger Jeff
Connolly Joe
H Collins Kathryn
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BR112012011783A2 publication Critical patent/BR112012011783A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória, via detecção à base de proteína de soro de composições de polímero de sequência aleatória. a presente invenção refere-se a métodos de detecção de peptídeos simples. contudo, os métodos para determinar a concentração de plasma efetiva de misturas de peptídeos como um grupo, perferivelmente do que para peptídeos individuais com uma sequência de aminoácido definida, são complicados pela heterogeneidade dos peptídeos a serem detectados. este pedido proporciona métodos aperfeiçoados de detectar e avaliar composições de polímero de seguência aleatória (rsp), métodos para a detecção e quantificação de composições de rsp, meios para determinar e enriquecer um subconjunto de peptídeos em uma composição de rsp baseados nas interações do indivíduo com certos polipeptídeos de captura, e métodos para administrar composições de rsp a um indivíduo em necessidade destas, no qual o regime de dosagem e quantidade podem ser determinados ou avaliados baseados nos métodos acima mencionados para detecção e quantificação.
BR112012011783A 2009-11-17 2010-11-17 "métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória via detecção à base de proteína de soro de composições de polímero de sequência aleatória." BR112012011783A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28147009P 2009-11-17 2009-11-17
US38690910P 2010-09-27 2010-09-27
PCT/US2010/057108 WO2011063045A1 (en) 2009-11-17 2010-11-17 Methods for improving the design, bioavailability, and efficacy of random sequence polymer compositions via serum protein-based detection of random sequence polymer compositions

Publications (1)

Publication Number Publication Date
BR112012011783A2 true BR112012011783A2 (pt) 2019-09-24

Family

ID=44059973

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012011824A BR112012011824A2 (pt) 2009-11-17 2010-11-17 processos para aprimoramento do planejamento da disponibilidade biológica e da eficácia de composições poliméricas com sequência direcionada através da detecção á base de proteínas do soro de composições poliméricas com sequência direcionada
BR112012011783A BR112012011783A2 (pt) 2009-11-17 2010-11-17 "métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória via detecção à base de proteína de soro de composições de polímero de sequência aleatória."

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012011824A BR112012011824A2 (pt) 2009-11-17 2010-11-17 processos para aprimoramento do planejamento da disponibilidade biológica e da eficácia de composições poliméricas com sequência direcionada através da detecção á base de proteínas do soro de composições poliméricas com sequência direcionada

Country Status (13)

Country Link
US (2) US8790665B2 (pt)
EP (2) EP2526419A4 (pt)
JP (2) JP2013511724A (pt)
KR (2) KR20120116414A (pt)
CN (2) CN102869989B (pt)
AU (2) AU2010322038A1 (pt)
BR (2) BR112012011824A2 (pt)
CA (2) CA2778705A1 (pt)
EA (2) EA022399B1 (pt)
IL (2) IL219742A0 (pt)
MX (2) MX2012005750A (pt)
WO (2) WO2011063045A1 (pt)
ZA (2) ZA201202854B (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6930168B2 (en) * 2001-01-24 2005-08-16 The President And Fellows Of Harvard College Synthetic peptides for demyelinating conditions
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ES2349033T3 (es) * 2001-12-04 2010-12-22 Teva Pharmaceutical Industries, Ltd. Procedimientos para la medida de la actividad del acetato de glatiramer.
US20090214580A1 (en) * 2004-02-02 2009-08-27 Houghten Richard A Peptide mixtures with immunomodulatory activity
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
CN101052409A (zh) * 2004-05-07 2007-10-10 肽免疫公司 用无规共聚物治疗疾病的方法
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
JP5297653B2 (ja) * 2004-10-29 2013-09-25 サンド・アクチエンゲゼルシヤフト グラチラマーの製造法
AU2006279557A1 (en) * 2005-08-15 2007-02-22 Wai Hong Chan Process for the preparation of copolymer-1
US20090036653A1 (en) * 2006-04-13 2009-02-05 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2016095A2 (en) * 2006-04-13 2009-01-21 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
DE602007003848D1 (de) * 2006-07-05 2010-01-28 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
EP2174130A2 (en) * 2007-06-21 2010-04-14 Momenta Pharmaceuticals, Inc. Copolymer assay
AU2009236583B2 (en) * 2008-04-17 2015-07-16 Declion Holdings Llc Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders

Also Published As

Publication number Publication date
EP2526420A1 (en) 2012-11-28
MX2012005749A (es) 2012-10-03
CN102869990A (zh) 2013-01-09
AU2010322038A1 (en) 2012-06-14
US20120276135A1 (en) 2012-11-01
BR112012011824A2 (pt) 2019-09-24
IL219741A0 (en) 2012-07-31
AU2010322036A1 (en) 2012-05-24
US8790665B2 (en) 2014-07-29
ZA201203527B (en) 2013-08-28
WO2011063045A1 (en) 2011-05-26
EA022399B1 (ru) 2015-12-30
JP2013511725A (ja) 2013-04-04
EP2526419A4 (en) 2013-09-18
CN102869989B (zh) 2015-04-29
US20120282296A1 (en) 2012-11-08
EP2526419A1 (en) 2012-11-28
ZA201202854B (en) 2013-06-26
EA201290347A1 (ru) 2012-12-28
JP2013511724A (ja) 2013-04-04
KR20120097520A (ko) 2012-09-04
KR20120116414A (ko) 2012-10-22
WO2011063043A1 (en) 2011-05-26
CA2778705A1 (en) 2011-05-26
EA201290345A1 (ru) 2012-12-28
CA2781153A1 (en) 2011-05-26
MX2012005750A (es) 2012-09-12
CN102869989A (zh) 2013-01-09
EP2526420A4 (en) 2013-09-18
IL219742A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
Trinh et al. iTRAQ-based and label-free proteomics approaches for studies of human adenovirus infections
WO2007127977A3 (en) Methods of evaluating peptide mixtures
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CN107531750B (zh) 多肽混合物高效液相色谱分析方法
BR112014027128A2 (pt) antígenos associados à próstata e regimes de imunoterapia baseada em vacina
RU2019132222A (ru) Ингибиторы ezh2 человека и способы их применения
US8329391B2 (en) Analysis of amino acid copolymer compositions
RU2015120601A (ru) Эритроферрон и erfe-полипептиды и способы регуляции метаболизма железа
BR9813841A (pt) Proteìna hmw da espécie chlamydia isolada, molécula de ácido nucleico isolada, vetor de expressão recombinante, célula hospedeira transformada, proteìna recombinante isolada ou fragmento ou análogo da mesma, composição imunogênica, composição antigênica, processos para produzir uma resposta imune em um animal, anti-soro, anticorpos, reagente diagnóstico, para detectar anticorpos anti-chlamydia em uma amostra de teste, para detectar a presença de chlamydia em uma amostra de teste, para prevenir, tratar ou melhorar um distúrbio relacionado com a chlamydia em um hospedeiro em necessdiade deste tratamento, e para determinar a presença de ácido nucleico codificando uma proteìna hmw ou um fragmento ou análogo da mesma em uma amostra, kits diagnósticos para detectar anticorpos para chlamydia, e para determinar a presença de ácido nucleico codificando uma proteìna hmw ou fragmento ou análogo da mesma em uma amostra, composição de vacina, e, composição farmacêutica
BR112012032206A2 (pt) comparações de amostras de proteínas
Gupta et al. Probing interactions between CLIP-170, EB1, and microtubules
BR112015008036A2 (pt) população de peptídeos isolados, método para detectar em uma amostra um anticorpo, método para diagnosticar erliquiose monocítica e/ou granulocítica e kit
HRP20160481T1 (hr) Peptidi za cjepiva protiv alergije na brezu
RU2008146997A (ru) Способ блокирования заражения флавивирусами молекулы и применения
BR112015005887A2 (pt) quantificação de tiroglobulina por espectroscopia de massa
BR112014013078A2 (pt) aparelho dental
BR112013031354A2 (pt) "método de perfilar uma amostra de um indivíduo para febre hemorrágica da dengue, método de identificação de um indivíduo com risco de febre hemorrágica da dengue e kit para a identificação de um indivíduo infectado pelo vírus da dengue"
Schwahn et al. Proteotyping to establish the lineage of type A H1N1 and type B human influenza virus
BR112012011783A2 (pt) "métodos para aperfeiçoar o desenho, biodisponibilidade e eficiência de composições de polímero de sequência aleatória via detecção à base de proteína de soro de composições de polímero de sequência aleatória."
Kori et al. A conventional procedure to reduce Asn deamidation artifacts during trypsin peptide mapping
Marsh et al. Determination of allergen levels, isoforms, and their hydroxyproline modifications among peanut genotypes by mass spectrometry
BR112023002580A2 (pt) Métodos para identificar a presença e/ou concentração e/ou quantidade de proteínas ou proteomas
ATE546731T1 (de) Schnelles homogenes immunoassay unter verwendung von elektrophorese
AR086924A1 (es) Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
WO2006089801A3 (de) Verfahren zum redox-potential-abhängigen nachweis von targetmolekülen durch wechselwirkende polypeptide

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.